Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for Aligos Therapeutics (ALGS) over the last 4 years, with Q3 2025 value amounting to $168000.0.

  • Aligos Therapeutics' Current Deferred Revenue changed N/A to $168000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $168000.0, marking a year-over-year change of. This contributed to the annual value of $151000.0 for FY2024, which is 8845.57% down from last year.
  • Aligos Therapeutics' Current Deferred Revenue amounted to $168000.0 in Q3 2025.
  • In the past 5 years, Aligos Therapeutics' Current Deferred Revenue ranged from a high of $7.6 million in Q1 2021 and a low of $151000.0 during Q4 2024
  • Its 4-year average for Current Deferred Revenue is $3.3 million, with a median of $1.3 million in 2023.
  • Examining YoY changes over the last 5 years, Aligos Therapeutics' Current Deferred Revenue showed a top increase of 8845.57% in 2024 and a maximum decrease of 8845.57% in 2024.
  • Quarter analysis of 4 years shows Aligos Therapeutics' Current Deferred Revenue stood at $6.6 million in 2021, then crashed by 80.29% to $1.3 million in 2023, then tumbled by 88.46% to $151000.0 in 2024, then increased by 11.26% to $168000.0 in 2025.
  • Its last three reported values are $168000.0 in Q3 2025, $579000.0 for Q2 2025, and $151000.0 during Q4 2024.